オハイオ州立大学脳神経外科、脳腫瘍幹細胞研究室のNakano Labでは、新たに１人、ポストドクトラルフェローを募集します。当研究室は２００６年にUCLAで立ち上げ、２００９年にOSUに移動して、脳腫瘍のシグナル伝達系の解析と、エピジェネテッティクス・ジェネティックス解析、得られた知見からの臨床治験のプロトコール作成と患者のリクルートなど、基礎研究から臨床応用まで幅広い医科学臨床研究を行っております。当研究室は決して大きなラボではありませんが（ポスドク２人、ヴィジティングフェロー２人、テクニシャン１人、医学部生１人）、米国内とカナダ、ヨーロッパ、韓国を中心に２０研究室を超える施設と共同研究を立ち上げており、がん研究における最先端のテーマについて、直接間接的に最先端の知見に接することができます。

グラント
American Cancer Society, 2008-2013, Role: PI, $729,000
NIH, PPG grant, 2013-2018, Role: PI for Core C, $10,463,675 (total), $500,000 (for Core C)
NIH, R01 grant, 2013-2018, Role: PI, $900,000
Sponsored Research Grant from 2 biotech companies

直近の論文は以下を参照ください。
２０１１年
1. Siomycin A depletes brain tumor stem cells partly through the MELK-mediated pathway. Nakano I (corresponding author), Inagaki A, Watanabe M, Lam D, Leung C, Visnyei K, Okemoto-Nakamura Y, Liang R, Mischel P, and Kornblum HI. Neuro-oncology 2011. 13(6):622-34.
2. Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens. Joshi K, Demir H, Miyazaki T, Yamada R, Ray-Chaudhury A, Nakano I. Journal of Visualized Experiment 2011. 53 doi: 10.3791/2846
3. CD44v6 regulates brain tumor stem cell growth partially through the AKT-mediated pathway. Jijiwa M, Demir H, Gupta S, Leung C, Joshi K, Orozco N, Huang T, Yildiz VO, Shibahara I, de Jesus JA, Yong WH, Mischel PS, Fernandez S, Kornblum HI and Nakano I. PLoS ONE 6(9): e24217. doi:10.1371/journal.pone.0024217
4. A molecular screening approach to identify and characterize inhibitors of glioblastoma multiforme stem cells. Visnyei K, Onodera H, Saigusa K, Damoiseaux R, Petrosyan S, De Vries D, Ferrari D, Saxe J, Panosyan E, Masterman-Smith M, Mottahedeh J, Huang J, Sabatti C, Nakano I and Kornblum HI. Molecular Cancer Therapeutics 2011 Oct;10(10):1818-28
5. Cancer Stem Cells in Pediatric Brain Tumors. Lasky JL, Choe M, and Nakano I. Cancer Stem Cells and Therapy 2009 Dec; 4(4):298-305
6. Editorial Finding drugs against CD133(+) glioma subpopulations. Nakano I, Chiocca EA. J Neurosurg. 2011 Mar;114(3):648; discussion 648-50.
7. Cancers and Cancer Stem Cells. Nakano I and Saya H No Shinkei Geka. 2010 Aug. Japanese
8. Brain tumor stem cells. Lasky JL and Nakano I. Current Signal Transduction Therapy 2011 [in press]
9. Glioma stem cells and their therapy resistance. Mangum R and Nakano I. Journal of Carcinogenesis and Mutagenesis 2011 [in press]

２０１２年
1. Telomestatin impairs glioma stem cell survival and growth trough the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb. (with the cover picture) Miyazaki T, Pan Y, Joshi K, Purohit D, Hu B, Demir H, Mazumder S, Okabe S, Yamori T, Viapiano M, Shin-ya K, Seimiya H, and Nakano I. Clin Cancer Res 2012 Mar 1;18(5):1268-80.
2. Laminin alpha 2 enables glioblastoma stem cell growth. Lathia JD, Li M, Gallagher J, Hall PE, Hale JS, Wu Q, Levy E, Venere M, M. Rani S, Huang P, Bae E, Selfridge J, Cheng L, Guvenc H, McLendon RE, Nakano I, Sloan AE, Bao S, Lai A, Gladson C, Bredel M, Hjelmeland AB, Rich JN. Annals of Neurology (in press)
3. Suppression of peroxiredoxin 4 in glioblastoma cells increases apoptosis and reduces tumor growth. Kim TH, Song J, Alcantara S, Murnan E, Liyanarachchi S, Palanichamy P, Yi JY, Viapiano MS, Nakano I, Yoon SO, Wu H, Parada LF, and Kwon CH. PLoS ONE (in press)
4. Blockade of EGFR signaling promotes glioma stem-like cell invasiveness by abolishing ID3-mediated inhibition of p27(KIP1) and MP3 expression. Jin X, Jin X, Sohn YW, Yin J, Kim SH, Joshi K, Nam DH, Nakano I, Kim H. Cancer Lett. 2012 Sep 27. pii: S0304-3835(12)00542-3. doi: 10.1016/j.canlet.2012.09.005.
5. A streamlined protocol for the use of the semi-sitting position in neurosurgery: A report on 48 consecutive procedures. Ammirati M, Lamki TT, Shaw AB, Forde B, Nakano I, Mani M. J Clin. Neurosci.[in press]]
6. Glioma Stem Cells: Their Role in Chemoresistance. Yamada R and Nakano I. World Neurosurgery 2012 [in press] doi:10.1016/j.wneu.2012.01.004
7. Characteristics of Brain Tumor Stem Cells and the Rationale for Applying Tyrosine Kinase Inhibitors as Potential Targeting Agents. Michael R. Mangum MR, Purohit D, and Nakano I. Recent Patents on Regenerative Medicine 2012 [in press]
8. Fluorescence-Guided Brain Tumor Surgery. Smith L and Nakano I. World Neurosurgery 2012 [in press]

2013年
1. Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin/Ran protein complex. Guvenc H*, Pavlyukov MS*, Kurt H, Joshi K Banasavadi-Siddegowda YK, Mao P, Hong C, Yamada R, Kwon CH, Kitange G, Park IH, Sarkaria JN, Li C, Shakhparonov MI, Nakano I. Clin Cancer Res 2013 Feb 1;19(3):631-42. doi: 10.1158/1078-0432.CCR-12-0647. Epub 2012 Dec 18
2. Tumor-specific activation of the c-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner. Gu C, Banasavadi-Siddegowda YK, Joshi K, Nakamura Y, Kurt H, Gupta S, and Nakano I. Stem Cells 2013 Jan 17. doi: 10.1002/stem.1322.
3. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Joshi K, Banasavadi-Siddegowda Y, Mo X, Kim S, Mao P, Kig C, Nardini D, Sobol RW, Chow L, Kornblum HI, Waclaw R, Beullens M, and Nakano I. Stem Cells 2013 Feb 13. doi: 10.1002/stem.1358.
4. Phosphorylation of a Polycomb component EZH2 by AKT activates STAT3 and promotes self-renewal and tumorigenicity of glioblastoma stem-like cells. Kim E, Kim M, ShinY, Joo KM, Woo DH, Chang N, Oh Y, Rheey J, Nakano I, Rich JN, Nam DH, Lee J. Cancer Cell [in press]
5. MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells. Peruzzi P, Bronisz A, Nowicki MC, Wang Y, Ogawa D, Price R, Nakano I, Kwon CH, Hayes J, Lawler SE, Ostrowski MC, Chiocca EA, Godlewski J. Neuro-oncology [in press]
6. Mesenchymal Glioma Stem Cells are Maintained by Activated Glycolytic Metabolism Involving Aldehyde Dehydrogenase 1A3. Mao P, Kim SH, Li J, Joshi K, Li PP, Santana-Santos L, Luthra S, Chandran UR, Benos PV, Smith L, Wang MD, Hu B, Cheng SY, Sobol RW, Nakano I. Proc Natl Acad Sci U S A. [in press]

投稿中の論文
当研究室から
1 paper is minor revision in PLoS One
共同研究として
1 paper is revised in Cell Stem Cell
1 paper is revised in Nature Neuroscience
1 paper is revised in Cell
2 papers are submitted to PLoS One
1 paper is submitted to Cancer Research

２０１３年の終わりまでには、cancer stem cellに関するゲノム異常の新規知見についてNature journalに２報投稿を目指しております。

基本的に受け入れたい方は、ガッツがあって米国（かそのほかの国）で独立を目指す能力のある方です。我こそと思われる方は、ぜひ連絡ください。グラントの取得、グリーンカードの取得、ファカルティーの職の取得など、数年前に私自身が通ってきた道を参考に、可能な範囲のサポートをします。技術的には、cell culture, stem cell culture, FACS, cell sort, transfection, lentiviral infection, siRNA/shRNA, site-directed mutagenesis, ChIP, IP-Western, qRT-PCR, ELISA, xenograft, mouse drug treatment, slice culture of patient tumorsなどを扱っていただきます。

有給で受け入れる方は、PhDを有し、first authorでcompetitiveな雑誌に論文がある方と限っております。無給で６－１２ヶ月トレーニングを受けて、次のステップを目指す方も喜んで受け入れます。

コロンバスは東海岸、西海岸と比較して6割程度の生活費で、ポスドクの給料でも家族を養える環境です。また、HONDAの拠点でもあり、日本人コミュニティーもしっかりしています。腹の座った方の応募をお待ちしております。

中野伊知郎
ichiro.nakano@osumc.edu

＊＊
Ichiro Nakano,MD, PhD
Associate Professor,
Director of Neural Cancer Stem Cell Program,
James Comprehensive Cancer Center,
Department of Neurosurgery,
The Ohio State University
Phone: 614-292-0358
Fax: 614-688- 4882